Cover Image
市場調查報告書

印度的肽、肝素市場 至2022年的預測:(胰島素,特立帕肽,利拉魯肽,Leuprolide,Exenatide,抑鈣素,Enoxaparin Sodium,肝素鈉

Indian Peptides and Heparin Market by Type (Insulin, Teriparatide, Liraglutide, Leuprolide, Leuprolide, Exenatide, Calcitonin, Enaxaparin Sodium, Heparin Sodium), Application (Diabetes, Infectious Diseases, Cancer, Osteoporosis) - Forecast to 2022

出版商 MarketsandMarkets 商品編碼 546072
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
印度的肽、肝素市場 至2022年的預測:(胰島素,特立帕肽,利拉魯肽,Leuprolide,Exenatide,抑鈣素,Enoxaparin Sodium,肝素鈉 Indian Peptides and Heparin Market by Type (Insulin, Teriparatide, Liraglutide, Leuprolide, Leuprolide, Exenatide, Calcitonin, Enaxaparin Sodium, Heparin Sodium), Application (Diabetes, Infectious Diseases, Cancer, Osteoporosis) - Forecast to 2022
出版日期: 2017年08月21日 內容資訊: 英文 77 Pages
簡介

印度的肽市場今後的年複合成長率 (CAGR) 為15.0%,2022年的市場規模估計達8億8300萬美元。還有國內肝素市場年複合成長率為4.9%,2022年的市場規模預計達1億7020萬美元。各種慢性疾病的患者增加,及政府的產業支援策略等,成為市場成長的原因。

本報告提供印度國內的肽及肝素的市場相關分析,各產品的特性,及市場基本結構及促進、阻礙因素,整體市場趨勢預測,各類型、各用途詳細趨勢,主要企業簡介、市場佔有率等調查。

第1章 印度的肽市場概要

  • 簡介
  • 市場動態
    • 推動因素
      • 各種疾病的發病數量的增加
      • 政府對製藥產業的積極行動
    • 阻礙因素
      • 替代性的醫藥品取得容易
    • 市場機會
      • 重量級肽的專利到期
    • 課題
      • 在法規方面、價格方面的課題

第2章 印度的肽市場:各類型

  • 簡介
  • 胰島素
    • 有開發中產品的企業
  • 特立帕肽
    • 有開發中產品的企業
  • 利拉魯肽
  • 醋酸Leuprolide
    • 有開發中產品的企業
  • OCTREOTIDE ACETATE
  • 鮭魚抑鈣素
  • TRIPTORELIN
  • EPTIFIBATIDE
  • GLATIRAMER ACETATE
  • BIVALIRUDIN
  • 升糖素
  • Exenatide
    • 有開發中產品的企業
  • 其他分子

第3章 印度的肽市場:各用途

  • 簡介
  • 糖尿病
  • 感染疾病
  • 癌症
  • 骨質疏鬆症
  • 心臟疾病
  • 婦產科病
  • 其他

第4章 印度的肽市場:佔有率分析

第5章 印度的肽市場:企業簡介 (產業概要,主要產品)

  • BIOCON LIMITED
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • WOCKHARDT LTD.
  • INTAS PHARMACEUTICALS LTD.
  • CIPLA LIMITED
  • EMCURE PHARMACEUTICALS PVT. LTD.
  • ZYDUS CADILA
  • BHARAT SERUM AND VACCINES LIMITED
  • NATCO PHARMA LIMITED
  • DR. REDDY'S LABORATORIES

第6章 印度的肝素市場:概要

  • 簡介
  • 市場動態
    • 推動因素
      • 血液凝固障礙的發病數量的增加
      • 政府對製藥產業的輔助
    • 阻礙因素
      • 市場集中度高:小規模企業進入市場的障礙
    • 課題
      • 在法規方面、價格方面的課題

第7章 印度的肝素市場:各類型

  • 簡介
  • Enoxaparin Sodium
    • 有開發中產品的企業
  • 肝素鈉
  • FONDAPARINUX
    • 有開發中產品的企業
  • DALTEPARIN SODIUM
    • 有開發中產品的企業

第8章 印度的肝素市場:佔有率分析

第9章 印度的肝素市場:企業簡介

  • CIPLA LTD.
  • EMCURE PHARMACEUTICALS PVT. LTD.
  • GLAND PHARMA LIMITED
  • TROIKAA PHARMACEUTICALS LTD.
  • BIOLOGICAL E LIMITED
  • BHARAT BIOTECH
  • SAMARTH LIFE SCIENCES PVT. LTD.
  • VHB LIFE SCIENCES LIMITED
  • CELON LABORATORIES PVT. LTD.
  • UNITED BIOTECH (P) LIMITED
目錄
Product Code: PH 5511

"Indian Peptides and Heparin Market projected to grow at a CAGR of 15.0% and 4.9% respectively"

The Indian peptides market is expected to reach USD 883.0 million in 2022 from USD 381.8 million in 2016 and is expected to register a CAGR of 15.0%, and the Indian heparin market is projected to reach USD 170.2 million by 2022, at a CAGR of 4.9%. Factors such as increasing prevalence of chronic diseases, increasing incidence of coagulation disorder, and favorable government policies are the major driving factors for the Indian peptides and heparin market. On the other hand, the availability of alternative drugs is the major restraining factor for the Indian peptides market. The patent expiry of blockbuster drugs will provide growth opportunities to players in the Indian peptides market. For example, Victorza is the brand name of the liraglutide peptide developed by Novo Nordisk. Its patent will expire in August 2017, which will enable drug manufacturers to introduce their generic versions of it.

"Bivalirudin type is expected to register the highest growth during the forecast period"

The Indian peptides market is classified on the basis of type into insulin, teriparatide, liraglutide, glucagon, leuprolide acetate, octreotide acetate, calcitonin salmon, triptorelin, eptifibatide, glatiramer acetate, bivalirudin, exenatide, and other molecules. The bivalirudin segment is expected to register the highest CAGR during the forecast period. This growth can be attributed to the increasing number of percutaneous coronary intervention procedures (PCI) in India.

"Awareness about early diagnosis drives growth of the diabetes segment"

By application, the Indian peptides market is segmented into diabetes, infectious disease, cancer, cardiology, osteoporosis, gynecological applications, and other applications. The diabetes segment is expected to register highest CAGR during the forecast period. The growth in this segment can be primarily attributed to increasing awareness of early diagnosis, increasing prevalence & incidence of diabetes, and increasing aging population.

Key players operating in the Indian peptides market include Abbott Laboratories (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy's Laboratories Limited (India), and Alkem Laboratories Limited (India).

"Enoxaparin sodium type is expected to register the highest growth during the forecast period"

The Indian heparin market is classified on the basis of type into enoxaparin sodium, heparin sodium, fondaparinux, and dalteparin sodium. The enoxaparin sodium type segment is expected to register the highest growth during the forecast period. This growth can be attributed to the increasing coagulation disorders in the country.

Key players operating in the Indian heparin market include Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (U.S.), Abbott Laboratories (U.S.), Lupin Ltd. (India), Dr. Reddy's Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd. (India), and VHB Lifesciences (India).

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Tier 1 - 70 %, Tier 2 - 30%
  • By Designation - C level - 62%, Director level - 21%, Others - 17%

Research Coverage:

The report analyses the Indian peptides market by type and application and the Indian heparin market by type. Apart from comprehensive product analysis and market sizing, the report also provides the complete list of peptide and heparin manufacturers and marketing players in India. In addition, the report profiles companies with product portfolios and key financial data by key players to maintain and increase their shares in the market. The abovementioned market research data, market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions to be successful in the market.

Benefits of Buying the Report:

This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.

The report provides insights on the following strategies:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the Indian peptides and heparin market. The report analyses the Indian peptides market by type and application and the Indian heparin market by type.
  • Competitive Assessment: In-depth assessment of the market strategies, business segments, and product portfolios of the leading players in the Indian peptides and heparin market.

TABLE OF CONTENTS

1. INDIAN PEPTIDES MARKET OVERVIEW

  • 1.1. INTRODUCTION
  • 1.2. INDIAN PEPTIDES MARKET DYNAMICS
    • 1.2.1. DRIVERS
      • 1.2.1.1. Rising incidence of diseases
      • 1.2.1.2. Favorable government initiatives for the pharmaceutical sector
    • 1.2.2. RESTRAINT
      • 1.2.2.1. Availability of alternative drugs
    • 1.2.3. OPPORTUNITY
      • 1.2.3.1. Patent expiry of blockbuster peptides
    • 1.2.4. CHALLENGE
      • 1.2.4.1. Regulatory and pricing issues

2. INDIAN PEPTIDES MARKET, BY TYPE

  • 2.1. INTRODUCTION
  • 2.2. INSULIN
    • 2.2.1. INSULIN MARKET : COMPANIES WITH PIPELINE PRODUCT
  • 2.3. TERIPARATIDE
    • 2.3.1. TERIPARATIDE ACETATE MARKET: COMPANIES WITH PIPELINE PRODUCTS
  • 2.4. LIRAGLUTIDE
  • 2.5. LEUPROLIDE ACETATE
    • 2.5.1. LEUPROLIDE ACETATE MARKET: COMPANIES WITH PIPELINE PRODUCTS
  • 2.6. OCTREOTIDE ACETATE
  • 2.7. CALCITONIN-SALMON
  • 2.8. TRIPTORELIN
  • 2.9. EPTIFIBATIDE
  • 2.10. GLATIRAMER ACETATE
  • 2.11. BIVALIRUDIN
  • 2.12. GLUCAGON
  • 2.13. EXENATIDE
    • 2.13.1. EXENATIDE MARKET: COMPANEIS WITH PIPELINE PRODUCTS
  • 2.14. OTHER MOLECULES

3. INDIAN PEPTIDES MARKET, BY APPLICATION

  • 3.1. INTRODUCTION
  • 3.2. DIABETES
  • 3.3. INFECTIOUS DISEASES
  • 3.4. CANCER
  • 3.5. OSTEOPOROSIS
  • 3.6. CARDIOLOGY
  • 3.7. GYNECOLOGY
  • 3.8. OTHER APPLICATIONS

4. INDIAN PEPTIDES MARKET SHARE ANALYSIS

5. INDIAN PEPTIDES MARKET COMPANY PROFILES (Business Overview, Products Offered)*

  • 5.1. BIOCON LIMITED
  • 5.2. SUN PHARMACEUTICAL INDUSTRIES LTD.
  • 5.3. WOCKHARDT LTD.
  • 5.4. INTAS PHARMACEUTICALS LTD.
  • 5.5. CIPLA LIMITED
  • 5.6. EMCURE PHARMACEUTICALS PVT. LTD.
  • 5.7. ZYDUS CADILA
  • 5.8. BHARAT SERUM AND VACCINES LIMITED
  • 5.9. NATCO PHARMA LIMITED
  • 5.10. DR. REDDY'S LABORATORIES

*Details on MarketsandMarkets view, Business Overview, Products Offered might not be captured in case of unlisted companies.

6. INDIAN HEPARIN MARKET OVERVIEW

  • 6.1. INTRODUCTION
  • 6.2. INDIAN HEPARIN MARKET DYNAMICS
    • 6.2.1. DRIVERS
      • 6.2.1.1. Growing incidence of coagulation disorders
      • 6.2.1.2. Government support for the pharmaceutical industry
    • 6.2.2. RESTRAINT
      • 6.2.2.1. High degree of consolidation to hinder small players from entering the market
    • 6.2.3. CHALLENGE
      • 6.2.3.1. Regulatory and pricing issues

7. INDIAN HEPARIN MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. ENOXAPARIN SODIUM
    • 7.2.1.1. Enoxaparin sodium market: Companies with pipeline products
  • 7.3. HEPARIN SODIUM
  • 7.4. FONDAPARINUX
    • 7.4.1.1. Fondaparinux market: Companies with pipeline products
  • 7.5. DALTEPARIN SODIUM
    • 7.5.1.1. Dalteparin sodium market: Companies with pipeline products

8. INDIAN HEPARIN MARKET SHARE ANALYSIS

9. INDIAN HEPARIN MARKET COMPANY PROFILES (Business Overview, Products Offered)*

  • 9.1. CIPLA LTD.
  • 9.2. EMCURE PHARMACEUTICALS PVT. LTD.
  • 9.3. GLAND PHARMA LIMITED
  • 9.4. TROIKAA PHARMACEUTICALS LTD.
  • 9.5. BIOLOGICAL E LIMITED
  • 9.6. BHARAT BIOTECH
  • 9.7. SAMARTH LIFE SCIENCES PVT. LTD.
  • 9.8. VHB LIFE SCIENCES LIMITED
  • 9.9. CELON LABORATORIES PVT. LTD.
  • 9.10. UNITED BIOTECH (P) LIMITED
  • 9.11. AUTHOR DETAILS

*Details on MarketsandMarkets view, Business Overview, Products Offered might not be captured in case of unlisted companies.

LIST OF TABLES

  • TABLE 1: INCIDENCE OF CANCER CASES IN INDIA, 2015 VS 2025
  • TABLE 2: PEPTIDES AND THEIR ALTERNATIVES
  • TABLE 3: INDIAN PEPTIDES MARKET, BY TYPE, 2016-2022 (USD MILLION)
  • TABLE 4: INSULIN MARKET: MANUFACTURERS AND BRANDS
  • TABLE 5: INSULIN MARKET: KEY PLAYERS AND BRANDS
  • TABLE 6: TERIPARATIDE ACETATE MARKET: MANUFACTURERS AND BRANDS
  • TABLE 7: TERIPARATIDE ACETATE MARKET: KEY PLAYERS AND BRANDS
  • TABLE 8: LIRAGLUTIDE MARKET: KEY PLAYERS AND BRANDS
  • TABLE 9: LEUPROLIDE ACETATE MARKET: MANUFACTURERS AND BRANDS
  • TABLE 10: LEUPROLIDE ACETATE MARKET: KEY PLAYERS AND BRANDS
  • TABLE 11: OCTREOTIDE ACETATE MARKET: MANUFACTURERS AND BRANDS
  • TABLE 12: OCTREOTIDE ACETATE MARKET: KEY PLAYERS AND BRANDS
  • TABLE 13: CALCITONIN-SALMON MARKET: MANUFACTURERS AND BRANDS
  • TABLE 14: CALCITONIN-SALMON MARKET: KEY PLAYERS AND BRANDS
  • TABLE 15: TRIPTORELIN MARKET: MANUFACTURERS AND BRANDS
  • TABLE 16: TRIPTORELIN MARKET: KEY PLAYERS AND BRANDS
  • TABLE 17: EPTIFIBATIDE MARKET: MANUFACTURERS AND BRANDS
  • TABLE 18: EPTIFIBATIDE MARKET: KEY PLAYERS AND BRANDS
  • TABLE 19: GLATIRAMER ACETATE MARKET: MANUFACTURERS AND BRANDS
  • TABLE 20: GLATIRAMER ACETATE MARKET: KEY PLAYERS AND BRANDS
  • TABLE 21: BIVALIRUDIN MARKET: MANUFACTURERS AND BRANDS
  • TABLE 22: BIVALIRUDIN MARKET: KEY PLAYERS AND BRANDS
  • TABLE 23: GLUCAGON MARKET: KEY PLAYERS AND BRANDS
  • TABLE 24: EXENATIDE MARKET: KEY PLAYERS AND BRANDS
  • TABLE 25: COLISTIN MOLECULE: MANUFACTURERES AND BRANDS
  • TABLE 26: COLISTIN MARKET: KEY PLAYERS AND BRANDS
  • TABLE 27: ENALAPRIL MOLECULE: MANUFACTURERES AND BRANDS
  • TABLE 28: ENALAPRIL MARKET: KEY PLAYERS AND BRANDS
  • TABLE 29: CASPOFUNGIN: MANUFACTURERES AND BRANDS
  • TABLE 30: CASPOFUNGIN MARKET: KEY PLAYERS AND BRANDS
  • TABLE 31: BORTEZOMIB: MANUFACTURERES AND BRANDS
  • TABLE 32: BORTEZOMIB MARKET: KEY PLAYERS AND BRANDS
  • TABLE 33: OXYTOCIN: MANUFACTURERS AND BRANDS
  • TABLE 34: OXYTOCIN MARKET: KEY PLAYERS AND BRANDS
  • TABLE 35: INDIAN PEPTIDES MARKET SIZE, BY APPLICATION, 2016-2022 (USD MILLION)
  • TABLE 36: INCIDENCE OF CANCER CASES IN INDIA, 2015 VS 2025
  • TABLE 37: INDIAN HEPARIN MARKET, BY TYPE, 2016-2022 (USD MILLION)
  • TABLE 38: ENOXAPARIN SODIUM MARKET: MANUFACTURERS AND BRANDS
  • TABLE 39: ENOXAPARIN SODIUM MARKET: KEY PLAYERS AND BRANDS
  • TABLE 40: HEPARIN SODIUM MARKET: MANUFACTURERS AND BRANDS
  • TABLE 41: HEPARIN SODIUM MARKET: KEY PLAYERS AND BRANDS 60  
  • TABLE 42: FONDAPARINUX MARKET: MANUFACTURERS AND BRANDS
  • TABLE 43: FONDAPARINUX MARKET: KEY PLAYERS AND BRANDS
  • TABLE 44: DALTEPARIN SODIUM MARKET: MANUFACTURERS AND BRANDS
  • TABLE 45: DALTEPARIN SODIUM MARKET: KEY PLAYERS AND BRANDS

LIST OF FIGURES

  • FIGURE 1: INDIAN PEPTIDES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 2: DRUG APPROVALS IN INDIA
  • FIGURE 3: OTHER MOLECULES: MARKET SHARE, 2016
  • FIGURE 4: INDIAN PEPTIDES MARKET SHARE, BY KEY PLAYER, 2016
  • FIGURE 5: COMPANY SNAPSHOT: BIOCON LIMITED (2016)
  • FIGURE 6: COMPANY SNAPSHOT: SUN PHARMACEUTICAL INDUSTRIES LTD (2016)
  • FIGURE 7: COMPANY SNAPSHOT: WOCKHARDT LTD. (2016)
  • FIGURE 8: COMPANY SNAPSHOT: INTAS PHARMACEUTICALS LTD (2016)
  • FIGURE 9: COMPANY SNAPSHOT: CIPLA LIMITED(2016)
  • FIGURE 10: COMPANY SNAPSHOT: ZYDUS CADILA (2016)
  • FIGURE 11: COMPANY SNAPSHOT: NATCO PHARMA LIMITED (2016)
  • FIGURE 12: COMPANY SNAPSHOT: DR. REDDY'S LABORATORIES (2016)
  • FIGURE 13: INDIAN HEPARIN MARKET: DRIVERS, RESTRAINTS, AND CHALLENGES
  • FIGURE 14: INDIAN HEPARIN MARKET SHARE, BY KEY PLAYER, 2016
  • FIGURE 15: COMPANY SANPSHOT: CIPLA LTD.
Back to Top